MYOS Corporation to Present Positive Clinical Data at 55th Annual Conference of the American College of Nutrition

CEDAR KNOLLS, NJ--(Marketwired - Oct 2, 2014) - MYOS Corporation ("MYOS" or the "Company") (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today the Company's abstract of a clinical study of Fortetropin^™ conducted in average, modestly trained males at the University of Tampa was accepted for poster presentation at the American College of Nutrition's 55^th Annual Conference focused on Translational Nutrition: Turning Research into Practice, being held October 15-18, 2014 in San Antonio, TX.

The abstract entitled, "A Novel Myostatin Inhibitor Increases Lean Body Mass and Muscle Thickness in Modestly Resistance Trained Males," highlights positive, statistically significant clinical trial results conducted at the Department of Health Sciences and Human Performance at The University of Tampa studying the effects of Fortetropin in modestly resistance trained males. Co-authors of the abstract are Jacob Wilson, Ph.D., CSCS*D, Assistant Professor and Director of the Skeletal Muscle and Sports Nutrition Laboratory at The University of Tampa, and Maghsoud Dariani, the head of science and technology at MYOS.

Robert Ashton, M.D., Chief Medical Officer of MYOS, commented, "We are pleased that our abstract has been selected for poster presentation at the American College of Nutrition's annual conference. The University of Tampa clinical study is extremely important for MYOS as it clearly demonstrates that the use of Fortetropin results in significant and impressive gains in muscle growth and lean body mass in recreationally trained individuals. We believe this is important because these subjects are more representative of the general population than the athletes and body builders so often studied. We look forward to presenting key findings from the study at this prestigious scientific congress."

Dr. Ashton concluded, "The compelling results of this study will help accelerate our efforts in building a portfolio of therapeutic products. We will continue studying Fortetropin's profound biological activity on overall health and longevity in many important clinical areas as we work to broaden our reach into the medical food and traditional therapeutic marketplace."

About MYOS Corporation
MYOS is an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin^™, the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as "The Muscle Company,"^™ visit www.myoscorp.com.

The Company's first commercial product containing Fortetropin (MYO-T12), is distributed by Maximum Human Performance (MHP) under the brand name MYO-X^® and is currently available on popular retailer websites including http://mhpstrong.com, www.bodybuilding.com, www.amazon.com and in specialty retailers including GNC and Vitamin Shoppe and others. MYOS believes that Fortetropin, as well as future products it envisions, will redefine existing standards for muscle health.

Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin^™ and its effects on myostatin inhibition, including our research and development activities described herein, product and customer demand, the continued growth of repeat purchases, market acceptance of our existing and future products including new products described herein, the ability to create new products through research and development, the continued growth in market expansion and revenue including the expansion into the age management market, the successful entry into new markets including the age management market, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin and MYO-X^®, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights and the issuance of the patent described herein, the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products, the ability to comply with NASDAQ's continuing listing standards, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.